Benefits of ADHD Treatment in Detained People
Recruiting · NCT05842330 · Interventional (participants receive a specific treatment) · Lead sponsor: Stéphanie Baggio
View the official record on ClinicalTrials.gov →Interventions studied
ConcertaPlacebo
What this trial is about
Attention deficit hyperactivity disorder (ADHD) is characterized by difficulties paying attention, poor impulse control, and hyperactive behaviors. It is associated with several health and social detrimental outcomes and leads to increased risks of criminality and recidivism. However, to date, ADHD treatment has been neglected in prison. This project will test the efficacy of ADHD treatment using a randomized controlled trial.
Who can take part
Age range
18 Years to 65 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 3
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- age between 18 and 65
- good command of French
- stay in prison approx. 4 months at eligibility visit
- endorsing clinical diagnostic criteria for DSM-5 ADHD
- providing written informed consent
Exclusion criteria
- presence of an acute uncontrolled comorbid psychiatric disorder
- medical contraindication to stimulant prescription
- potential adverse interaction with another medication
- already receive ADHD treatment
Where it is running
1 location listed.
- Geneva University Hospitals - Geneva, Canton of Geneva, Switzerland